A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide,
Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin,
Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This Phase III, randomized, double-blind, placebo-controlled study will compare the
safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants
with previously untreated diffuse large B-cell lymphoma (DLBCL).
Study Contact InformationStudy Coordinator: Reference Study ID Number: GO39942 www.roche.com/about_roche/roche_worldwide.htm
Phone: 888-662-6728 (U.S. and Canada)
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search